Clinical Analysis Of The Diagnosis And Treatment Of Pancreatic Cancer And The Efficacy Of Gemcitabine-Based Chemotherapy

Objective: In recent years, pancreatic cancer’s morbidity is increasingyear by year in the world, most of the patients of diagnosis has advanced,because of its fast progression, hiding beginning, so far there is no effectivetreatment options. early diagnosis and treatment are pancreatic cancer treatmentof the key. for patients of advanced Panereatic cancer,gemcitabine for first-linetreatment of pancreatic cancer drugs, can improve patients’ quality of life.clinical analysis of patients with pancreatic cancer in the Second Hospital ofJilin University， Compares the efficacy of gemeitabine-based combinationtherapy and gemeitabine alone on advanced Panereatic cancer.Methods: Clinical data of252patients with pancreatic cancerundergone different treatment in the Second Hospital of Jilin University fromJanuary2006to January2009were using the software of SPSS11.5forstatisties,43case among the252case of pancreatic cancer were reviewed andanalyzed retrospectively, and gemcitabine-combination regimens withgemcitabine alone regimens in the clinical efficacy, disease control rate, medianoverall survival time and toxicity reactions carried out comparative.Results: Of the252cases of pancreatic cancer, the positive rates ofultrasound, CT, enhanced CT and MRCP were89.56%,93.67%,94.44%,90.63%,the positive rates of CA-199, CEA, AFP were61.17%,14.29%,6.67%；Earlydiagnosis can improve the curative resection rate of pancreatic cancer. TNMstaging and survival rates between the statistically significant. Compare to thegroups of palliative resection,bypass,and no operative therapy, the medianoverall survival and1,2,3-year survival rate is higher of patients after radicalresection (P <0.01), however there are no difference among the groups of palliative resection,bypass,and no operative therapy (P>0.05).Palliative chemotherapy in patients with gemcitabine combinationregimens in the clinical efficacy, disease control rate, median overall survivaltime were higher than gemcitabine alone regimens, but between the two groupswere not statistically significant (P>0.05).Conclusions1. The number of men’s morbidity is moer than women’s for pancreaticcancer, and the peak age is after60years old.2. the early symptoms of pancreatic cancer is not typical, and oftenjaundice, abdominal pain does not ease are found.3. Color Doppler Ultrasound, CT, CA199, etc. can be used as a means ofscreening high-risk pancreatic cancer populations.4. The early diagnosis of pancreatic cancer, help to improve the survivalrate and quality of production. The radical resection is still the most effectiveprocedure to the pancreatic carcer.5. Palliative chemotherapy in patients with advanced pancreatic cancer,gemcitabine-combination regimens compared with gemcitabine alone regimens,clinical efficacy, disease control rate and median overall survival did notsignificantly improve.